Search
Filters
Clear All
  • 5

Phase

  • 4
  • 5
  • 2

Found 5 patrick-loehrer-md trials

A listing of patrick-loehrer-md medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Molecular and Pathological Correlates of Treatment Outcome in Patients with Thymoma and Thymic Carcinoma

P
Patrick Loehrer, MD
1-100 years
All genders
What is this study about?The major purpose of this research study is to obtain blood samples from child and adult patients diagnosed with thymoma and/or tissue samples from patients undergoing surgery for their thymoma.  We will use these specimens to test for certain characteristics that we think will be useful …
Learn More

Phase II Trial of Panitumumab Nivolumab and Ipilimumab for KRAS/NRAS/BRAF Wild-type MSS Refractory Metastatic Colorectal Adenocarcinoma

P
Patrick Loehrer, MD
18-100 years
All genders
The purpose of this research study is to learn more about the safety and anti-cancer activity of a 3-drug combination therapy involving antibodies nivolumab, ipilimumab and panitumumab.
Learn More

Phase II Randomized Double-Blind Study of mFOLFIRINOX plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients HCRN GI14-198

18-100 years
All genders
The purpose of this study is to find out what effects, good and/or bad, there are to adding the drug ramucirumab (RAM) to the usual chemotherapy regimen.
Learn More

Tissue Procurement Protocol for the Developmental Therapeutics Clinic National Cancer Institute (NCI)

A
Anna Maria Storniolo, MD
All genders
The purpose of this study is to obtain samples for research purposes from tests performed for clinical indications or research indications on other research protocols, and to obtain samples for research purposes from non-surgical procedures, performed for the sole purpose of obtaining samples for this protocol.
Learn More

A Phase I/II, Open-Label Study to Investigate the Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics of GSK3145095 Administered Alone and in Combination With Anticancer Agents Including Pembrolizumab in Adult Participants With Selected Advanced Solid Tumors

P
Patrick Loehrer, MD
18-100 years
All genders
In an unbiased CRISPR screen, RIPK1 was identified as a top gene contributing to immunotherapy resistance. In addition, RIPK1 has been reported to drive pancreatic oncogenesis. In murine models, inhibition of RIPK1 kinase activity in the pancreatic tumor microenvironment leads to the replacement of tumor-permissive myeloid infiltrates with innate cells …
Learn More